vs

Side-by-side financial comparison of Infobird Co., Ltd (IFBD) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.

Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.4M, roughly 1.1× Infobird Co., Ltd). On growth, Infobird Co., Ltd posted the faster year-over-year revenue change (17118.0% vs -10.2%).

Infobird Co., Ltd. is a China-based technology firm specializing in AI-powered customer engagement and smart customer service solutions. It serves clients across e-commerce, finance, telecommunications, and internet service sectors, offering cloud-based SaaS tools, intelligent call center systems, and customized digital operation support to help enterprises boost service efficiency and customer satisfaction.

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

IFBD vs IRD — Head-to-Head

Bigger by revenue
IRD
IRD
1.1× larger
IRD
$3.9M
$3.4M
IFBD
Growing faster (revenue YoY)
IFBD
IFBD
+17128.1% gap
IFBD
17118.0%
-10.2%
IRD

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
IFBD
IFBD
IRD
IRD
Revenue
$3.4M
$3.9M
Net Profit
$-1.6M
Gross Margin
37.2%
Operating Margin
-31.8%
Net Margin
-46.7%
Revenue YoY
17118.0%
-10.2%
Net Profit YoY
-98.1%
53.0%
EPS (diluted)
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IFBD
IFBD
IRD
IRD
Q4 25
$3.9M
Q3 25
$3.1M
Q2 25
$3.4M
$2.9M
Q1 25
$4.4M
Q4 24
$4.3M
Q3 24
$3.9M
Q2 24
$1.1M
Q1 24
$1.7M
Net Profit
IFBD
IFBD
IRD
IRD
Q4 25
Q3 25
$-17.5M
Q2 25
$-1.6M
$-7.4M
Q1 25
$-8.2M
Q4 24
Q3 24
$-7.5M
Q2 24
$-7.8M
Q1 24
$-7.1M
Gross Margin
IFBD
IFBD
IRD
IRD
Q4 25
Q3 25
Q2 25
37.2%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IFBD
IFBD
IRD
IRD
Q4 25
Q3 25
-269.9%
Q2 25
-31.8%
-309.0%
Q1 25
-227.2%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
Q1 24
-450.5%
Net Margin
IFBD
IFBD
IRD
IRD
Q4 25
Q3 25
-566.9%
Q2 25
-46.7%
-257.5%
Q1 25
-187.5%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
Q1 24
-415.3%
EPS (diluted)
IFBD
IFBD
IRD
IRD
Q4 25
Q3 25
$-0.25
Q2 25
$-0.41
$-0.12
Q1 25
$-0.24
Q4 24
Q3 24
$-0.29
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IFBD
IFBD
IRD
IRD
Cash + ST InvestmentsLiquidity on hand
$698.0K
$45.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$66.7M
$15.3M
Total Assets
$72.4M
$50.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IFBD
IFBD
IRD
IRD
Q4 25
$45.1M
Q3 25
$30.8M
Q2 25
$698.0K
$32.4M
Q1 25
$41.8M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
Q1 24
$47.2M
Stockholders' Equity
IFBD
IFBD
IRD
IRD
Q4 25
$15.3M
Q3 25
$6.0M
Q2 25
$66.7M
$17.5M
Q1 25
$5.1M
Q4 24
$6.7M
Q3 24
$34.3M
Q2 24
$40.6M
Q1 24
$46.1M
Total Assets
IFBD
IFBD
IRD
IRD
Q4 25
$50.2M
Q3 25
$36.1M
Q2 25
$72.4M
$38.7M
Q1 25
$48.2M
Q4 24
$36.9M
Q3 24
$40.4M
Q2 24
$44.8M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IFBD
IFBD
IRD
IRD
Operating Cash FlowLast quarter
$1.1M
$-35.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IFBD
IFBD
IRD
IRD
Q4 25
$-35.3M
Q3 25
$-6.2M
Q2 25
$1.1M
$-10.3M
Q1 25
$-9.0M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M
Q1 24
$-5.7M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons